Clinical development is the process of testing a new drug or biologic in humans to prove it is safe and effective enough to earn regulatory approval. It sits at the center of a longer drug development pipeline: after a compound is discovered in a lab and tested in animals (preclinical research), clinical development begins with the first dose given to a human and continues through large-scale trials that generate the evidence regulators need. The entire process typically costs hundreds of millions of dollars per approved drug, takes years to complete, and follows a structured sequence of phases, each with a distinct purpose.
Where Clinical Development Fits in the Pipeline
The FDA describes drug development as a five-step process: discovery, preclinical research, clinical research, regulatory review, and post-market safety monitoring. Clinical development corresponds to step three, clinical research, but it also overlaps with step five because Phase 4 studies continue after a drug reaches the market. Before any human testing begins, a company must file an Investigational New Drug application with the FDA, presenting preclinical data from lab and animal studies that suggest the drug is reasonably safe to try in people.
Phase 0: Microdosing
Some development programs include an optional Phase 0 study before formal Phase 1 trials. In these exploratory studies, a tiny, sub-therapeutic dose of the drug is given to a small number of volunteers. The dose is so low it produces no pharmacological effect and is not expected to cause side effects. The goal is purely informational: researchers track how the body absorbs, distributes, and eliminates the compound. This pharmacokinetic snapshot helps teams decide early whether a molecule behaves well enough in humans to justify the expense of a full Phase 1 program.
Phase 1: Finding a Safe Dose
The primary objective of a Phase 1 trial is to determine the dose that will be used in later studies, known as the recommended Phase 2 dose. Researchers also identify the drug’s most important side effects and establish the highest dose patients can tolerate before toxicity becomes unacceptable.
These trials typically enroll 20 to 80 participants, often healthy volunteers, though cancer drugs are usually tested in patients with advanced disease who have exhausted standard options. A common design starts with just three people at the lowest dose level. If none experience a serious side effect, the next three receive a slightly higher dose. If one person does have a significant reaction, three more are added at that same level before any escalation continues. To reliably detect a side effect that occurs in 5% of patients, researchers need roughly 57 to 82 participants.
The starting dose itself is chosen conservatively. For most drugs, it is set at one-tenth the dose that was lethal in mice, or one-sixth the highest dose that did not cause severe toxicity in a more sensitive animal species such as monkeys. For particularly risky compounds, regulators recommend a calculation based on the lowest dose expected to have any biological effect at all.
Phase 2: Testing for Efficacy
Phase 2 trials shift the focus from safety to whether the drug actually works. The central question is whether the treatment shows enough promise to justify a large, expensive Phase 3 trial. These studies typically enroll tens to a few hundred patients who have the disease the drug is intended to treat.
The most common measure of efficacy at this stage is objective response rate: the proportion of patients whose disease visibly shrinks or resolves. But endpoints are evolving. Quality-of-life scores, symptom reduction, and toxicity comparisons are increasingly used as primary measures, especially in designs that blend Phase 2 and Phase 3 into a single seamless trial. Phase 2 is also where researchers refine the dose-response relationship, testing whether a lower dose can deliver similar benefit with fewer side effects.
Many drugs fail here. A treatment might control symptoms in a small, tightly selected group but not well enough to outperform existing options in a broader population. Phase 2 results determine whether a company commits the much larger investment required for Phase 3.
Phase 3: Proving the Drug Works at Scale
Phase 3 trials are the pivotal studies that regulators rely on most heavily when deciding whether to approve a drug. They enroll 300 to 3,000 volunteers who have the target disease or condition and typically run for one to four years. The FDA generally requires adequate data from two large, controlled trials before a company can file for approval.
“Controlled” means the study is designed to minimize bias. Participants are usually randomly assigned to receive either the new drug or an existing standard treatment (or a placebo when no standard exists). Neither patients nor their doctors may know which group they are in. This rigorous design is what separates clinical development from anecdotal evidence: it produces the statistical confidence needed to say a drug truly offers a benefit.
Phase 3 also continues to monitor adverse reactions. Because the participant pool is much larger and more diverse than in earlier phases, side effects that were too rare to appear in Phase 1 or 2 may surface for the first time.
Regulatory Review and Approval
Once Phase 3 data are compiled, the company submits a formal application to regulators. For conventional drugs, this is a New Drug Application. For biological products like vaccines, antibodies, and gene therapies, it is a Biologics License Application. Both filings include the full package of evidence: preclinical data, manufacturing details, clinical trial results from all phases, and proposed labeling that describes how the drug should be used.
Regulatory scientists then review the data independently, sometimes convening advisory committees of outside experts. The review weighs the drug’s benefits against its risks for the specific population studied. Approval is not the end of clinical development; it marks a transition into the final phase.
Phase 4: Real-World Monitoring
Phase 4 studies begin after a drug reaches the market. No matter how many patients are studied before approval, certain risks only become visible when hundreds of thousands or millions of people use a drug in everyday conditions. Adverse reactions that occur in fewer than 1 in 3,000 to 5,000 patients are unlikely to be detected during pre-approval trials and may be completely unknown at the time of approval. Rare but serious effects, like the blood disorders historically seen with certain antibiotics, can only be caught through ongoing surveillance.
Phase 4 also tests something fundamentally different from earlier phases: effectiveness versus efficacy. Pre-approval trials use strict enrollment criteria, close monitoring, and enforced compliance. In the real world, patients have varying organ function, take other medications, and don’t always follow instructions precisely. Post-marketing studies measure how a drug performs under those messy, realistic conditions. These studies sometimes reveal new uses for a drug that warrant formal investigation, or they generate safety signals that lead to label changes or, in rare cases, withdrawal from the market. Safety monitoring continues for the entire life of a drug.
How Long It Takes and What It Costs
The full clinical development timeline, from the first human dose through regulatory approval, commonly spans six to ten years. Phase 3 alone accounts for one to four years, and earlier phases add several more. Regulatory review adds additional months.
Cost estimates vary widely depending on what is counted. A 2024 analysis published in JAMA Network Open estimated the mean cost of developing a single new drug at roughly $173 million in 2018 dollars, including post-marketing studies. That figure reflects only the successful molecule. When the costs of drugs that failed during development are factored in (since companies must fund many candidates to get one across the finish line), the average rises to about $516 million. Adding the cost of capital, the money tied up for years that could have been invested elsewhere, pushes the fully loaded estimate to approximately $879 million per approved drug. Costs vary enormously by therapeutic area, ranging from around $379 million for anti-infectives to over $1.7 billion for pain and anesthesia drugs.
Ethical and Quality Standards
Every clinical trial operates under a framework called Good Clinical Practice, an international set of principles that govern how trials are designed, conducted, and reported. GCP exists to protect participants and ensure that the resulting data are reliable. It spells out specific responsibilities for investigators who run the trial, sponsors who fund it, monitors who audit it, and institutional review boards that provide independent oversight. The core commitment is straightforward: the rights, safety, and well-being of human subjects take priority over the interests of science or commerce. No trial can proceed without informed consent from participants and approval from an independent ethics board.